Agenus shared a post on LinkedIn:
“A newly published ESMO analysis compared outcomes from botensilimab + balstilimab with current standards of care in refractory MSS metastatic colorectal cancer, highlighting differences in survival outcomes and safety profiles across treatment approaches.
Independent, hypothesis-generating analyses like this are an important part of advancing the field and helping contextualize emerging data and inform future research questions.
We appreciate the role of rigorous, independent evaluation as the oncology community continues working toward better options for patients with high unmet need. Read the publication.”
Title: Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care
Authors: Elisabetta Bengala, Daniele Santini, Vincenzo Picone
Read The Full Article
More posts about Agenus on OncoDaily.